Heart failure & cardiomyopathies
Prognostic Value of Gut Microbe-Generated Metabolite Phenylacetylglutamine in Patients with Heart Failure
Main finding · 5-year all-cause mortality (Cleveland cohort)Result — go to the resultAdjusted hazard ratio 1.64 95% CI 1.07–2.53Authors' conclusion
High levels of PAGln are associated with adverse outcomes independent of traditional cardiac risk factors and cardio-renal risk markers.
Study context
- Population
- Patients with stable heart failure (HF) from two large cohorts (Cleveland and Berlin)
- Exposure
- Highest vs lowest quartile of plasma phenylacetylglutamine (PAGln)
- Outcome
- All-cause mortality (Cleveland cohort)
- Follow-up
- 5-year follow-up
Methodological detailstwo cohorts (Cleveland, Berlin), Fasting plasma PAGln measured by stable-isotope-dilution LC-MS/MS
- Two cohorts (Cleveland, Berlin)
- Fasting plasma PAGln measured by stable-isotope-dilution LC-MS/MS
Main finding
5-year all-cause mortality (Cleveland cohort) · 5 years
Adjusted hazard ratio
1.64
95% CI 1.07–2.53
Q4vs Q1
adjusted HR 1.64 (95% CI 1.07–2.53)
As reported in the abstract
- Unadjusted mortality risk, highest vs lowest quartile
- 3.09-fold
- Median PAGln (Cleveland)
- 4.2 (IQR 2.4-6.9) μM
Observational data: associations, not effects.
Further findings
| Outcome | Adjusted HR (95% CI) | |
|---|---|---|
| HF hospitalization or all-cause mortality (Berlin cohort) · 3 years | 1.92 (1.02–3.61) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
- HF hospitalization or all-cause mortality (Berlin cohort) — Median PAGln (Berlin)
- 3.2 (IQR 2.0-4.8) μM
Independence from trimethylamine N-oxide
- Prognostic value of PAGln appears independent of trimethylamine N-oxide levels
Original publication
Prognostic Value of Gut Microbe-Generated Metabolite Phenylacetylglutamine in Patients with Heart Failure. Eur J Heart Fail. Published 25 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →